Drilldown: Medicines
Appearance
Medicines > onset
:
Bronchodilation within 1-2 hours; full controller effect 1-2 weeks
or
LDL lowering at 2 weeks, max by 4 weeks
& duration:
24 hours 
:
Bronchodilation within 1-2 hours; full controller effect 1-2 weeks
or
LDL lowering at 2 weeks, max by 4 weeks
& duration:
24 hours 
Use the filters below to narrow your results.
2.7-5.5 hours'"`UNIQ--ref-0000015E-QINU`"' (1) ·
~2-3 hours (parent); pharmacodynamic effect 24 hours via target turnover'"`UNIQ--ref-000003D5-QINU`"' (1) ·
~2-4 hours (parent and active β-hydroxy acid metabolite); pharmacodynamic effect 24 hours via target turnover'"`UNIQ--ref-00000807-QINU`"' (1)
<5% (extensive hepatic first-pass; food enhances absorption of IR, hence the evening-meal dosing)'"`UNIQ--ref-00000808-QINU`"' (1) ·
~17% (oral; food slightly reduces absorption)'"`UNIQ--ref-000003D6-QINU`"' (1) ·
~64% (oral; not significantly affected by food)'"`UNIQ--ref-0000015F-QINU`"' (1)
Generally considered safe; pregnancy registries do not show increased major malformation risk.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Previously Category X; FDA removed the blanket statin contraindication in pregnancy in 2021.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2)
[[USLegal:Prescription only|Rx-only]] in US (2) ·
[[USLegal:Prescription only|Rx-only]] in US. '''FDA Boxed Warning (2020):''' neuropsychiatric events including agitation, depression, sleep disturbance, and suicidal thoughts; benefit-risk should be reassessed regularly'"`UNIQ--ref-00000160-QINU`"'. (1)
Showing below up to 3 results in range #1 to #3.

